Skip to main content

Table 2 Baseline characteristics and doses of anti-tuberculosis medications

From: Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar

 

FDC (n = 90)

ST (n = 58)

Age in years, mean ± SD

34.3 ± 10.1

33.4 ± 10.2

Male gender, n (%)

83 (92.2)

44 (75.9)

Asian nationalitya, n (%)

80 (88.9)

49 (84.5)

BMI (kg/m2), mean ± SDb

20.3 ± 3.1

20.5 ± 3.2

Diabetes, n (%)

19 (21.1)

14 (24.1)

Hypertension, n (%)

4 (4.4)

3 (5.2)

Smoking, n (%)

40 (44.4)

11 (19)

Vitamin D level (ng/ml), mean ± SDc

19.7 ± 10

18.5 ± 6.2

Isoniazid (mg/kg), mean ± SD

4.8 ± 0.4

5.5 ± 1

Rifampin (mg/kg), mean ± SD

9.6 ± 0.9

10 ± 1.2

Pyrazinamide (mg/kg), mean ± SD

25.8 ± 2.2

23.4 ± 2.3

Ethambutol (mg/kg), mean ± SD

17.7 ± 1.7

17 ± 5.7

+++ AFB load, n (%)

34 (37.8)

24 (41.4)

  1. AFB acid-fast bacilli, BMI body mass index, FDC fixed-dose combination, ST separate tablets
  2. aSouth Asian and Southeast Asian nationalities including Indian, Nepalese, Pakistani, Bangladeshi, Sri Lankan, Indonesian, and Filipino
  3. bData available for 81 (FDC group) and 55 (ST group) patients
  4. cData available for 68 (FDC group) and 49 (ST group) patients
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us